← Who reports today · Health Care
How CVS Health (CVS) makes money: Q3 2026 revenue breakdown
Net income (loss) attributable to CVS Health
$2,172M
Total revenues
$108,399M
up 5.4% y/y
Operating income (loss)
$3,566M
Next report
~ Feb 9
not announced yet
The quarter in brief
Revenue $108.40B (+5.4% y/y), operating income $3.57B, net income $2.17B.
Key growth driver: Products — the fastest-growing revenue line: $69,225, +7% y/y. · by the Q3 2026 report
How does CVS Health make money?
CVS Health brought in $108 billion of revenue in Q3 2026, up 5.4% year over year. The largest source was Products: $69.2 billion, or 64% of the total, followed by Premiums ($34.6B, 32%) and Services ($3.96B, 4%); other lines add the remaining 0.6%. Net income for the quarter was $2.17 billion.
Revenue by source, Q3 2026
- Products$69.2B · 64% · +7.2%
- Premiums$34.6B · 32% · +2.5%
- Services$3.96B · 4% · +0.8%
- Net investment income$647M · 0.6% · +2.4%
Shares of $108B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
All figures in $M.
| Line item | Amount and change |
|---|---|
| Products | $69,225 · +7.2% |
| Premiums | $34,566 · +2.5% |
| Services | $3,961 · +0.8% |
| Net investment income | $647 · +2.4% |
| Total revenues | $108,399 · +5.4% |
| Cost of products sold | $61,185 · +7.3% |
| Health care costs | $32,316 · +0.9% |
| Operating expenses | $11,332 · +0.4% |
| Operating income (loss) | $3,566 · vs −$3,207 · 3.3% margin |
| Interest expense | $747 · −4.7% |
| Other income | $30 · +15.4% |
| Income (loss) before income tax provision | $2,849 · vs −$3,482 |
| Income tax provision | $678 · +33.5% · 23.8% effective rate |
| Net (income) loss attributable to noncontrolling interests | $1 · −93.3% |
| Net income (loss) attributable to CVS Health | $2,172 · vs −$3,975 · $1.68/sh · 2.0% margin |
Verdict: revenue $108.40B (+5.4% y/y), operating income $3.57B, net income $2.17B.
CVS raised its full-year 2026 GAAP diluted EPS guidance to at least $6.98 from a range of $6.84 to $7.04, and its adjusted EPS guidance to at least $8.20 from $7.90 to $8.10. Full-year 2026 total revenues are projected at at least $420.0 billion. Cash flow from operations guidance was raised to at least $15.5 billion from at least $11.5 billion, after $15.3 billion was generated year to date. Dividends paid in the first nine months totaled $2,578 million.
Source and notation
Source: CVS Health earnings release, 8-K EX-99 of 11/04/2026 (SEC EDGAR).
Open as an image: CVS Health (CVS), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “CVS Health (CVS) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/cvs. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/cvs"><img src="https://whoreportstoday.com/t/cvs/img/cvs-health-earnings-sankey.png" alt="CVS Health (CVS) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/cvs">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/cvs/img/cvs-health-earnings-sankey.png
<a href="https://whoreportstoday.com/t/cvs">CVS Health (CVS) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- The quarter included a $193 million Omnicare guarantee charge in operating expenses; the prior-year quarter included a $483 million gain on the deconsolidation of Omnicare.
- In Health Care Benefits, the medical benefit ratio improved to 91.3% from 92.8%, and adjusted operating income rose to $912 million from $314 million.
- Health Services revenue grew 9.5% to $53,964 million, while Pharmacy & Consumer Wellness revenue fell 2.0% to $35,498 million.
- Interest expense declined to $747 million from $784 million.
- The income tax provision was $678 million, an effective rate of about 23.8% on pre-tax income of $2,849 million.
- Diluted shares rose to 1,291 million from 1,269 million.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- J. David JoynerChairman of the Board and Chief Executive Officer [1]
- Brian O. NewmanExecutive Vice President and Chief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- CVS HealthnowPresident and Chief Executive Officer
- gWell2021–2023Strategic Business Advisor
- Podimetrics2020–2023Advisor
Source: SEC EDGAR: 10-K annual report, 2026-02-10 · as of 10/21/2026
- CVS Healthsince 2025Executive Vice President and Chief Financial Officer
- United Parcel Service2019–2024Executive Vice President and Chief Financial Officer
Source: SEC EDGAR: 10-K annual report, 2026-02-10 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-11-04 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-11-04 · SEC EDGAR · 11/18/2026
CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. · Text: Wikipedia, CC BY-SA 4.0, abridged
The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.
Company reports
Company guidance
Same quarter a year ago (ended December 31, 2025): revenue $105.7B, EPS (GAAP) $2.31
How we calculate
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
CVS earnings history: past report dates
| Nov 4, 2026 Wed | 6:31 ambefore market open | Sep 30, 2026 | $108B+5% y/y | $1.68 |
| Aug 5, 2026 Wed | 6:32 ambefore market open | Jun 30, 2026 | $106B+7% y/y | $2.31+189% y/y |
| May 6, 2026 Wed | 6:31 ambefore market open | Mar 31, 2026 | $100B+6% y/y | $2.30+63% y/y |
| Feb 10, 2026 Tue | 6:31 ambefore market open | Dec 31, 2025 | ≈$106B+8% y/y | ≈$2.31+78% y/y |
| Oct 29, 2025 Wed | 6:32 ambefore market open | Sep 30, 2025 | $103B+8% y/y | −$3.13 |
| Jul 31, 2025 Thu | 6:31 ambefore market open | Jun 30, 2025 | $98.9B+8% y/y | $0.80−43% y/y |
| May 1, 2025 Thu | 6:32 ambefore market open | Mar 31, 2025 | $94.6B+7% y/y | $1.41+60% y/y |
| Feb 12, 2025 Wed | 6:32 ambefore market open | Dec 31, 2024 | ≈$97.7B+4% y/y | ≈$1.30−18% y/y |
| Nov 6, 2024 Wed | 6:33 ambefore market open | Sep 30, 2024 | $95.4B+6% y/y | $0.07−96% y/y |
| Aug 7, 2024 Wed | 6:33 ambefore market open | Jun 30, 2024 | $91.2B+3% y/y | $1.41−5% y/y |
| May 1, 2024 Wed | 6:32 ambefore market open | Mar 31, 2024 | $88.4B+4% y/y | $0.88−47% y/y |
| Feb 7, 2024 Wed | 6:33 ambefore market open | Dec 31, 2023 | ≈$93.8B+12% y/y | ≈$1.59−10% y/y |
| Nov 1, 2023 Wed | 6:35 ambefore market open | Sep 30, 2023 | $89.8B+11% y/y | $1.75 |
| Aug 2, 2023 Wed | 6:34 ambefore market open | Jun 30, 2023 | $88.9B+10% y/y | $1.48−35% y/y |
| May 3, 2023 Wed | 6:34 ambefore market open | Mar 31, 2023 | $85.3B+11% y/y | $1.65−7% y/y |
| Feb 8, 2023 Wed | 6:32 ambefore market open | Dec 31, 2022 | ≈$83.8B+9% y/y | ≈$1.77+70% y/y |
Show all 16 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
CVS Health: 15-year financials
| 2025 | 402,067 | 4,660 | 1,768 | 7,807 | 3,397 |
| 2024 | 372,809 | 8,516 | 4,614 | 6,326 | 3,373 |
| 2023 | 357,776 | 13,743 | 8,344 | 10,395 | 3,132 |
| 2022 | 322,467 | 7,954 | 4,311 | 13,450 | 2,907 |
| 2021 | 292,111 | 13,310 | 8,001 | 15,745 | 2,625 |
| 2020 | 268,706 | 13,911 | 7,179 | 13,428 | 2,624 |
| 2019 | 256,776 | 11,987 | 6,634 | 10,391 | 2,603 |
| 2018 | 194,579 | 4,021 | −594 | 6,828 | 2,038 |
| 2017 | 184,786 | 9,538 | 6,622 | 6,089 | 2,049 |
| 2016 | 177,546 | 10,386 | 5,317 | 7,917 | 1,840 |
| 2015 | 153,290 | 9,475 | 5,237 | 6,172 | 1,576 |
| 2014 | 139,367 | 8,799 | 4,644 | 6,001 | 1,288 |
| 2013 | 126,761 | 8,037 | 4,592 | 3,799 | 1,097 |
| 2012 | 123,120 | 7,210 | 3,864 | 4,641 | 829 |
| 2011 | 107,080 | 6,331 | 3,462 | 3,984 | 674 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
CVS Health: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 253,538 | 75,214 | 64,570 | 8,453 | 74,714 | 88,692 |
| 2024 | 253,215 | 75,560 | 66,270 | 8,586 | 68,645 | 84,609 |
| 2023 | 249,728 | 76,461 | 61,610 | 8,196 | 67,858 | 79,189 |
| 2022 | 228,275 | 71,469 | 52,254 | 12,945 | 65,633 | 69,421 |
| 2021 | 232,999 | 75,075 | 56,176 | 9,408 | 60,008 | 67,807 |
| 2020 | 230,715 | 69,389 | 64,647 | 7,854 | 56,369 | 62,017 |
| 2019 | 222,449 | 63,864 | 68,480 | 5,683 | 50,302 | 53,303 |
| 2018 | 196,456 | 58,225 | 74,149 | 4,059 | 45,243 | 44,009 |
| 2017 | 95,131 | 37,691 | 28,278 | 1,696 | 31,229 | 30,648 |
| 2016 | 94,462 | 36,830 | 27,574 | 3,371 | 31,042 | 26,250 |
| 2015 | 92,437 | 37,196 | 27,500 | 2,459 | 29,158 | 23,169 |
| 2014 | 74,187 | 37,958 | 12,985 | 2,481 | 25,983 | 19,027 |
| 2013 | 71,526 | 37,938 | 13,400 | 4,089 | 25,325 | 15,425 |
| 2012 | 66,221 | 37,653 | 9,790 | 1,375 | 20,161 | 14,150 |
| 2011 | 64,852 | 38,013 | 10,050 | 1,413 | 18,594 | 11,956 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 15,318 | 7,249 | +8,069 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 3,373 | 3,459 | |
| · incl. stock-based comp (non-cash)share-based compensation | 610 | 400 | |
| Capexpurchases of property & equipment | −2,357 | −2,048 | −309 |
| Free cash flow ≈operating cash flow − capex | 12,961 | 5,201 | +7,760 |
| Investing activities, netcapex, acquisitions, securities | −5,545 | −3,873 | −1,672 |
| · incl. acquisitionsbusinesses net of cash acquired | −15 | −429 | +414 |
| Financing activities, netdebt, buybacks, dividends | −6,537 | −2,908 | −3,629 |
| · incl. buybacksrepurchases of common stock | — | 0 | |
| · incl. dividends paid | −2,578 | −2,552 | −26 |
| Net change in cash | 3,236 | 468 | +2,768 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 30, 2026: $80.5B (31% of total assets). Compare with other S&P 500 companies →
Corporate governance
2/2good
- Feb 20262025 10-K cover: a single class — Common Stock, $0.01 (NYSE: CVS). sec.gov ↗
- Feb 2026Diluted share count −3.3% over 2020–2025; SBC of $535M = 0.1% of $402B revenue (XBRL). data.sec.gov ↗
2 more facts and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Feb 2026Per-share dividend: $2.00 in 2017–2021, $2.20 in 2022, $2.42 in 2023, $2.66 in 2024–2025 — no cuts (XBRL). data.sec.gov ↗
- Feb 2026The 2019 class actions over the LTC business were dismissed by the courts (the last in Feb. 2025, under appeal); the 2024 suits over insurance-segment profitability are unresolved. sec.gov ↗
Scoring: 2.0 with no deductions = 2.0 (single share class, shares −3.3% over 5 years, dividend never cut, 2019 class actions dismissed by the court, 2024 suits unresolved)
- Share classes
- Single class of common stock (10-K cover: Common Stock, NYSE).
- Dilution
- Diluted shares −3.3% over 2020–2025, SBC 0.1% of revenue; buybacks of $8.5B over 2022–2024.
- Disclosure
- Full 10-K/10-Q reporting.
- Dividends
- $2.00 per share frozen in 2018–2021 (deleveraging after the Aetna acquisition), then $2.20 → $2.66; no cuts.
- Lawsuits & regulators
- 2019 suits (LTC/Omnicare): City of Miami — dismissed (affirmed by the 1st Circuit in 2022), City of Warren — dismissed 2023, Waterford — dismissed 2025 (on appeal); 2024 suits (Louisiana Sheriffs, SDNY) — at the motion stage, unresolved → no deduction. Opioid settlements are industry-wide, not a criterion.
- Related parties
- No material related-party transactions in the 2026 proxy.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies with revenue growth 10 years in a row · S&P 500 companies that paid dividends 10 years without a gap
CVS Health (CVS) earnings: FAQ
How does CVS Health make money?
CVS Health brought in $108 billion of revenue in Q3 2026, up 5.4% year over year. The largest source was Products: $69.2 billion, or 64% of the total, followed by Premiums ($34.6B, 32%) and Services ($3.96B, 4%); other lines add the remaining 0.6%. Net income for the quarter was $2.17 billion.
When is CVS's next earnings date?
We have not yet seen an announcement of the date from CVS Health (CVS). Based on last year's report on Feb 10, 2026, the next report is expected around Feb 9, 2027.
What time does CVS report earnings?
CVS Health usually reports before market open: its latest results release was filed with the SEC at 6:31 am ET on Nov 4, 2026.
When did CVS last report earnings?
CVS Health reported Q3 2026 results on Nov 4, 2026.
Where can I find CVS Health's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to CVS's filings; this page breaks the latest report down in a Sankey chart.
What was CVS's net income in Q3 2026?
CVS Health reported net income of $2,172M for Q3 2026 (vs −$3,975 year over year), under US GAAP.
Does CVS Health pay dividends?
Yes. In 2025, CVS Health paid $3,397M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has CVS Health's revenue changed since 2011?
Per its 10-K filings, revenue grew 3.8x: $107,080M in 2011 and $402,067M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: DGX · Q3 2026 · DHR · Q3 2026 · DVA · Q3 2026 · DXCM · Q3 2026 · ELV · Q3 2026 · EW · Q2 2026 · GEHC · Q3 2026 · GILD · Q3 2026 · HCA · Q3 2026 · HSIC · Q3 2026 · all reports